Department of Dermatology, College of Medicine, Chang Gung Memorial Hospital, Keelung, Linkou, Taipei, Taiwan.
Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei, Taiwan.
J Immunol Res. 2018 Jan 17;2018:5376476. doi: 10.1155/2018/5376476. eCollection 2018.
Cutaneous adverse drug reactions are commonly seen in patients with anticancer drug treatment. Anticancer drugs, including chemotherapy, target therapy, and recent immunotherapy causing skin reactions ranging from mild skin rash to life-threatening severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrosis (TEN) with increase morbidity and mortality while they are receiving cancer treatments, have been proposed to be a result of direct skin toxicity or drug hypersensitivity reactions (these are proposed mechanism, not definite). Differentiating SCARs from other more commonly seen reactions with a better outcome help prevent discontinuation of therapy and inappropriate use of systemic immunosuppressants for presumable allergic reactions, of which will affect the clinical outcome. In this article, we have reviewed published articles from 1950 to August 2017 for SJS/TEN associated with anticancer drugs, including chemotherapy, targeted therapy, and immunotherapy. We aimed to provide an overview of SJS/TEN associated with anticancer drugs to increase clinician recognition and accelerate future studies on the pathomechanism and managements.
皮肤不良反应在接受抗癌药物治疗的患者中很常见。抗癌药物,包括化疗、靶向治疗和最近的免疫治疗,可导致皮肤反应,从轻度皮疹到危及生命的严重皮肤不良反应(SCAR),如史蒂文斯-约翰逊综合征(SJS)和中毒性表皮坏死松解症(TEN),这些不良反应会增加发病率和死亡率,同时也会影响癌症治疗。人们认为这些不良反应是直接皮肤毒性或药物过敏反应的结果(这些是提出的机制,不是确定的)。区分 SCAR 与其他更常见的、预后较好的反应有助于预防因推测的过敏反应而停止治疗和不恰当地使用全身性免疫抑制剂,这会影响临床结果。本文综述了 1950 年至 2017 年 8 月发表的与抗癌药物(包括化疗、靶向治疗和免疫治疗)相关的 SJS/TEN 相关文章。旨在概述与抗癌药物相关的 SJS/TEN,以提高临床医生的认识,并加速对发病机制和管理的未来研究。